NCT02418689已完成2 期
A Prospective, Open-label, Single-arm, Multi-Center, Phase II Trial of NOV120101 in Patients With HER2-overexpressed Recurrent Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens
Hanmi Pharmaceutical Company Limited7 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2015年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 106
- 试验地点
- 7
- 主要终点
- Progression free survival (PFS)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), in HER2-overexpressed recurrent stage IV breast cancer patients who received at least 2 prior HER2-directed regimens.
详细描述
To evaluate the efficacy of NOV120101 (Poziotinib) as a therapeutic agent for HER2-overexpressed recurrent stage IV breast cancer, patients who have received at least two prior HER2-directed regimens will be enrolled in this study. Subjects will receive NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by 1-week drug-free intervals between cycles until disease progression or unacceptable toxicity development. Progression Free Survival (PFS) will be analyzed as the primary endpoint in this trial. Secondary endpoints including PFS rate at 12 weeks, ORR, DCR, OS and TTP will also be analyzed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Who give agreement to the collection of tumor tissue specimen suitable for biomarker research
- •ECOG performance status ≤ 2
- •Who received following treatments as Taxane-based chemotherapy and at least two HER2-targeted* therapy including Trastuzumab.
- •* lapatinib, T-DM1 (trastuzumab emtansine), pertuzumab
- •Adequate hematological, hepatic and renal functions
排除标准
- •Who received NOV120101 prior to participation in this study
- •Patients expected to exhibit hypersensitivity to IP or its components
- •Any other concurrent chemotherapies
- •Concurrent or prior radiotherapy within 4 weeks before study participation. However, patients with additional lesions other than the major lesion who completed and recovered from all treatment-related toxicities after radiotherapy in a limited area as a palliative therapy are allowed to participate in the study
- •History of symptomatic or unstable angina and congestive heart failure; arrhythmia requiring medications; or clinically significant myocardial infarction or other cardiac diseases within 6 months before study participation for which any related-significant risks are expected
- •Patients whose left ventricle ejection fraction (LVEF) is below the institutional lower limit of normal. However, if no lower limit of normal is defined in the site, the lower limit or normal is 50%.
- •Concurrent active hepatic or biliary disease (with exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver diseases)
- •History or concurrent ongoing/active infection, or uncontrolled diseases including, but not limited to, psychiatric illness/social situations which may limit the compliance with study procedures
- •Prior chemo-, immuno-, or surgical therapy within 3 weeks, or hormone therapy within 1 week before IP administration
- •History of primary malignancies other than breast cancer.
- •Patients with central nervous system (CNS) metastases.
- •Patients receiving or expected to receive bisphosphonate for prophylactic use without any bone-related diseases during the trial, for the exception of the treatment for bone metastases or osteoporosis initiated prior the IP administration.
- •Clinically significant or recent acute gastrointestinal disorders with diarrhea as a major symptom
- •Who are unstable or with unresolved severe adverse event(s)
- •Pregnancy or breast-feeding
- •Women of childbearing potential or men who are unwilling to use adequate contraception or be abstinent during the trial and for at least 2 months after the end of treatment
研究组 & 干预措施
NOV120101 (Poziotinib)
Experimental
Single arm study with NOV120101(poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval
干预措施: NOV120101 (Poziotinib) (Drug)
结局指标
主要结局
Progression free survival (PFS)
时间窗: By 12 months after enrollment of the last subject
次要结局
- PFS rate at Week 12(12 weeks)
- Objective Response Rate (ORR)(By 12 months after enrollment of the last subject)
- Disease Control Rate (DCR)(By 12 months after enrollment of the last subject)
- Duration of Disease Control(By 12 months after enrollment of the last subject)
- Overall Survival (OS)(By 12 months after enrollment of the last subject)
- Time To Progression (TTP)(By 12 months after enrollment of the last subject)
- Duration of objective response(By 12 months after enrollment of the last subject)
- Time to objective response(By 12 months after enrollment of the last subject)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
1 期
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced TumorsAdvanced CancerNCT02407990BeiGene451
已完成
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HR011408 at Two Formulations in Healthy SubjectDiabetes in AdultsNCT05147259Jiangsu HengRui Medicine Co., Ltd.62
已完成
1 期
ONO-4538 Phase I Study in Patients With Solid TumorAdvanced Solid TumorsRecurrent Solid TumorsNCT02261298Ono Pharmaceutical Co. Ltd18
已完成
1 期
Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid TumorsSolid TumorsNCT02610361BeiGene131
已完成
1 期
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsNeoplasms MalignantNCT04047290Akesobio Australia Pty Ltd80